20 Future Hungarian HealthTech and MedTech Leaders

Nelson Advisors
16 hours ago
14 min read

The Evolution of Hungarian Life Sciences: 20 Future Leaders in HealthTech and MedTech

The landscape of Hungarian healthcare innovation has transitioned from a historical foundation of pharmaceutical excellence into a dynamic, multi-disciplinary ecosystem defined by medical deep tech, artificial intelligence and sophisticated biotechnology. This transformation is anchored by a strategic shift in the country’s academic and financial infrastructure, moving toward a "fourth-generation" research model where knowledge transfer and commercialization are prioritized alongside academic inquiry.

Between 2015 and 2025, over €925 million in venture capital flowed into the Hungarian startup ecosystem, with the life sciences sector, encompassing pharmaceuticals, biotechnology and MedTech, securing a significant portion of this investment. This growth is not accidental but is the result of a coordinated effort by state agencies, university-led technology transfer centers, and a new generation of scientists-turned-entrepreneurs who are bridging the gap between the laboratory bench and the patient's bedside.

The Institutional and Economic Framework of Innovation

The maturation of the Hungarian HealthTech sector is facilitated by a robust institutional framework. The National Research, Development and Innovation Office (NRDIO) has launched successive programs aimed at fostering the startup ecosystem, while the Hungarian Innovation Agency (HIA) has focused on developing "Deep Tech" capabilities.

A critical component of this framework is the emergence of university-owned Technology Transfer Companies (TTCs), such as the Semmelweis Technology Transfer Company Ltd (SE TTC), established in 2024. These entities act as conduits between academic researchers and market players, translating scientific breakthroughs into commercially viable products.

Furthermore, the University of Szeged (SZTE) has established a comprehensive innovation incubation environment, including the Science Park Szeged and various "Advanced Core Facilities" (ACF) ranging from pharmaceutical research to 3D materials science. This institutional support is complemented by the presence of large-scale research infrastructures like the ELI-ALPS Laser Research Centre and the Szeged Biological Research Centre (HUN-REN BRC).

Ecosystem Component	Primary Function	Key Participating Entities
State Agencies	Policy, Funding, Infrastructure	NRDIO, HIA, Hungarian Innovation Hub
Venture Capital	Seed to Series C Funding	Hiventures, PortfoLion, Oktogon Ventures
Academic Pillars	Research, Clinical Trials, Spin-offs	Semmelweis (SOTE), SZTE, Pázmány Péter
Accelerators	Mentorship, Validation, Scaling	EIT Health InnoStars, Health Venture Lab

The economic profile of this sector is characterized by increasing deal sizes and more frequent funding rounds. In the first half of 2025, the top ten Hungarian funding rounds reached a total of €41.2 million, a stark increase from €15.4 million in the same period in 2023. This capital is increasingly directed toward companies that leverage AI to solve complex biological problems, reflecting a global trend toward "TechBio".

Profile of Oncology and Personalised Medicine Leaders

The most advanced segment of the Hungarian HealthTech market is oncology, where the integration of computational modelling and molecular biology is revolutionising drug discovery and clinical decision-making.

1. Szabolcs Nagy (Turbine AI)

Szabolcs Nagy, the CEO and co-founder of Turbine AI, represents a new breed of leadership that balances biological complexity with computational scalability. Under his guidance, Turbine has emerged as a global leader in "in silico" drug discovery. The company’s core technology is a Simulated Cell platform that models how cancer cells respond to various treatments at the molecular level, allowing researchers to test millions of drug combinations before entering a physical laboratory.

The implications of Nagy’s leadership are profound for the pharmaceutical industry. By identifying the most effective drug combinations early in the development cycle, Turbine significantly reduces the probability of clinical trial failure. This approach is particularly critical in oncology, where the heterogeneity of tumors often renders standard-of-care treatments ineffective. Turbine’s success, highlighted by a $30.7 million Series A round in late 2022 from investors like Accel and Mercia, positions Nagy as a central figure in the European "TechBio" revolution.

2. Kristóf Szalay (Turbine AI)

As the CTO and co-founder of Turbine AI, Kristóf Szalay is the technical architect behind the Simulated Cell platform.His work focuses on translating the intricate signaling networks of cancer biology into a predictive mathematical framework. The challenge he addresses is the sheer scale of biological data; a single human cell contains thousands of interacting proteins, and understanding how a specific mutation or drug affects this network requires immense computational power.

Szalay’s contribution lies in the development of algorithms that can accurately simulate these interactions, providing a "digital twin" of a cancer cell. This enables a level of precision in drug screening that was previously impossible. The partnership between Nagy’s strategic vision and Szalay’s technical depth has allowed Turbine to partner with major pharmaceutical companies to accelerate their oncology pipelines.

3. István Peták (Genomate Health)

István Peták, the founder of Genomate Health, is a pioneer in the field of precision oncology. His work addresses the "N-of-1" challenge: the need to tailor cancer treatment to the specific genetic profile of an individual patient. Genomate Health develops AI-driven computational models that standardise clinical decision-making by automating the synthesis of vast amounts of genomic and clinical data.

Peták’s vision is to make precision medicine the standard of care globally. His company’s flagship product assists physicians in identifying the most effective therapeutic options for patients who have exhausted traditional treatments. With a total funding of approximately $10.03 million and a presence in both Budapest and Cambridge, Massachusetts, Peták is bridging the Hungarian research tradition with the world’s most advanced biotech markets.

4. Zalán Péterfi (VRG Therapeutics)

Zalán Péterfi, a Harvard-trained scientist and former McKinsey consultant, serves as the Chairman and Managing Director of VRG Therapeutics. His background uniquely positions him to lead a company focused on the intersection of scientific excellence and business execution. VRG Therapeutics specialises in miniprotein-based biopharmaceuticals and cell and gene therapy.

Péterfi’s leadership is defined by the use of an AI-powered miniprotein platform that can discover validated hit molecules within six months—a process that typically takes years using traditional screening methods. This efficiency is a critical competitive advantage in the high-stakes world of biotech. VRG's recent expansion into the Netherlands and its participation in major international gene therapy forums illustrate Péterfi’s ambition to scale Hungarian innovation on a global stage.

5. Péter Horváth (HCS-3DX / HUN-REN BRC)

Péter Horváth, a researcher at the HUN-REN Szeged Biological Research Centre, has developed a system that could revolutionize the scale of personalized medicine. The HCS-3DX technology integrates artificial intelligence, light-sheet microscopy, and automated sample handling to analyze up to one hundred patient cell samples simultaneously.

Horváth’s work addresses the bottleneck in personalized medicine: the slow and manual evaluation of 3D cell samples (spheroids). By automating the selection and handling of these samples using the "SpheroidPicker" micromanipulator, his system brings industrial-scale speed to cell analysis. The goal is to use a patient’s own 3D cell model to determine which treatment will work best for them in real-time, effectively bringing the laboratory's precision directly to the patient's bedside.

Leaders in Biotechnology and Life Science Systems

The broader biotechnology sector in Hungary is being redefined by leaders who are applying biological principles to solve systemic problems in drug safety, environmental sustainability, and cellular manipulation.

6. Attila Csikász-Nagy (Cytocast)

Attila Csikász-Nagy, the CEO of Cytocast and a professor at Pázmány Péter Catholic University, is a visionary in computational systems biology. Cytocast, a spin-off from the university, focuses on "whole-cell simulation," a technique used to predict how drugs will affect cellular networks and to anticipate potential side effects.

The significance of Csikász-Nagy’s work lies in its potential to de-risk drug development. Many drugs fail in clinical trials because they interact with non-target proteins, leading to toxicity. By simulating the entire cell, Cytocast can identify these risks before a drug ever enters a human subject. This systemic approach is essential for the next generation of safe and effective biopharmaceuticals.

7. Terje Wimberger (Cellectric Biosciences)

Terje Wimberger is the Managing Director and co-founder of Cellectric Biosciences, a company that is pioneering the use of electromagnetic fields for cell manipulation. Following the unexpected passing of co-founder Klemens Wassermann in 2025, Wimberger has led the company as it commercialises its "electrome manipulation" technology.

The core innovation of Cellectric is the ability to selectively rupture specific cell types—such as human cells in a blood sample—while leaving others, like bacteria, intact. This has profound implications for the rapid diagnosis of sepsis and other life-threatening infections. By "upgrading" traditional laboratory techniques with electromagnetic precision, Wimberger and his team are creating tools that allow for instant diagnosis and more efficient bioprocessing.

8. Liz Madaras (Poliloop)

Liz Madaras, a pharmaceutical chemist engineer and CEO of Poliloop, has gained international recognition for her work in environmental biotechnology. Along with co-founder Krisztina Lévay, she developed a bacterial cocktail capable of degrading single-use plastics into biomass and valuable end-products within weeks.

While primarily an environmental startup, Poliloop represents a critical advancement in biological engineering. Madaras’s work demonstrates how nature’s own metabolic processes can be harnessed to solve industrial waste problems. Her leadership has secured investment from prestigious accelerators like Techstars and recognition on the Forbes 30 Under 30 list. As the healthcare industry grapples with the immense volume of plastic waste generated by hospitals, Poliloop's technology offers a path toward a circular bio-economy.

9. Krisztina Lévay (Poliloop)

Krisztina Lévay, the CTO and co-founder of Poliloop, is the technical mastermind behind the company’s bacterial degradation process. With a background in pharmaceutical engineering and chemistry, she led the two-year research effort to create the "bacterial cocktail" that integrates the carbon from fossil-based plastics into its metabolism.

Lévay’s role is essential for scaling the technology from the laboratory to industrial testing. Her expertise in research design and team management has allowed Poliloop to navigate the complexities of microbial biodegradation. Together with Madaras, she is proving that Hungarian biotech can address some of the world's most pressing environmental and logistical challenges.

10. Tamás Martinek (University of Szeged)

Professor Tamás Martinek at the University of Szeged is a leader in the development of targeted drug delivery systems.His research focuses on enabling biologically derived therapeutic agents, which typically act only on the cell surface—to enter the human cell and exert their effects internally.

Martinek’s breakthrough solution uses a high-affinity oligopeptide tagging sequence that mimics the entry mechanisms of certain viruses, allowing macromolecules to access the cell via the caveolar pathway. This technology platform has the potential to unlock a new class of intracellular biologics. A spin-off company has already been established to advance this technology into the next phase of development and clinical trials.

MedTech Leaders: Redefining Diagnostics and Rehabilitation

The Hungarian MedTech sector is particularly strong in the development of hardware-software hybrids that utilise sensors and AI to monitor vulnerable populations and assist in physical recovery.

11. Péter Földesy (NICOWL)

Péter Földesy is the CEO of NICOWL, a MedTech startup that is transforming care in Neonatal Intensive Care Units (NICUs). NICOWL’s AI-powered intelligent video surveillance system automatically assesses infant positioning, detects crying episodes, and monitors sleep-wake states in premature babies.

The clinical relevance of Földesy’s work is significant. Every hour a premature infant spends in the wrong position or is disturbed during sleep can result in neurological damage. NICOWL’s technology allows for 24/7, non-contact monitoring that reduces nurse workload while improving the developmental outcomes for newborns. With clinical validation data approaching human-level agreement, Földesy is leading the company through the rigorous MDR certification process to deploy this innovation across Europe.

12. Krisztina Katalin Puskás (GraphoPen)

Krisztina Katalin Puskás and her team developed the GraphoPen, a tool that has won numerous awards for its role in stroke patient rehabilitation. The device uses neural stimulation and precise measurement to assist patients in regaining motor control and evaluating their progress during the rehabilitation process.

The GraphoPen exemplifies the Hungarian focus on "Medical Device Innovation" that combines hardware with sophisticated data tracking. By providing a measurable and interactive way for patients to engage with their therapy, Puskás is addressing a critical need in long-term neurological care, where consistency and accurate tracking of progress are key to successful outcomes.

13. Bertalan Jászkuti (Syreon Research Institute)

As the CEO of Syreon Research Institute, Bertalan Jászkuti is a leader in health economics and outcomes research, which are increasingly vital for the adoption of new MedTech solutions. His work involves evaluating the cost-effectiveness and clinical impact of new medical technologies, ensuring that they can be integrated into public healthcare systems.

Jászkuti’s role is critical because innovation in MedTech is not just about a functioning device; it is about proving to insurers and governments that the device improves patient health at a sustainable cost. His expertise helps Hungarian startups navigate the complex path from clinical validation to market access and reimbursement.

14. Gábor Orbán (Richter Gedeon)

While Richter Gedeon is a large, established pharmaceutical company, its CEO Gábor Orbán has been recognized as the "Most Inspiring Leader of the Year" for his role in modernizing the firm and fostering a culture of innovation. Under his leadership, Richter has increasingly focused on the development of biologics and biosimilars, a high-growth area that requires sophisticated biotechnological capabilities.

Orbán’s leadership is significant for the broader ecosystem because Richter Gedeon acts as a major anchor and potential partner for smaller HealthTech startups. By steering one of Hungary’s most successful companies toward a more innovative and collaborative future, Orbán is ensuring that the traditional strengths of the Hungarian pharma industry are leveraged in the new digital and biological age.

15. András Sápi (Verdant Catalyst)

Dr. András Sápi, a researcher at the University of Szeged, received the SZTE Innovation Award for the commercialization of his "catalytic brick" technology through the spin-off Verdant Catalyst Kft. While the invention targets environmental pollution, its primary impact is on public health, specifically the reduction of respiratory diseases caused by wood-burning and mixed-fuel heating systems.

Sápi’s work represents a practical, market-ready solution to a widespread environmental health problem in Central Europe. The catalytic brick integrates into furnaces and fireplaces, reducing carbon monoxide and particulate matter emissions while improving heating efficiency. His successful journey from laboratory research to a commercially available product serves as a model for other academic innovators in the Hungarian ecosystem.

Leaders in Digital Health and Behavioural Science

The digital transformation of healthcare in Hungary is being driven by leaders who understand that technology must be paired with human behaviour insights and accessible platforms.

16. Tamás Petrovics (XUND)

Tamás Petrovics is a co-founder of XUND, a health-tech company that provides an API-first medical device to connect patients to the appropriate care. XUND's platform uses sophisticated algorithms to analyse symptoms and guide patients through the entire journey from prevention to diagnosis.

The success of Petrovics’s vision is evident in XUND’s funding history, which includes a €6 million seed round in 2025 from a diverse group of international and local investors. By providing a structured and medically validated way for patients to interact with their health data, XUND is helping to reduce the burden on primary care physicians and ensure that patients receive the right care at the right time.

17. Rachel Altmann (BeHive Consulting)

Rachel Altmann is the CEO and co-founder of BeHive Consulting, a behavioral science firm based in Budapest. Along with her co-founders, she applies insights from psychology and neuroscience to design science-backed solutions that influence human behaviour in the healthcare sector.

Altmann’s leadership has been particularly impactful in public health. BeHive has worked with the World Health Organization (WHO) to design EU-wide strategies to reduce alcohol consumption and has optimised hospital vaccination processes during the pandemic. By addressing the "human factor" in healthcare, such as patient adherence and medical professional burnout, Altmann is providing a missing piece in the innovation puzzle.

18. Noémi Molnár (BeHive Consulting)

Noémi Molnár, the Chief Behavioural Scientist at BeHive Consulting, is responsible for the academic rigor and scientific methodology of the firm’s interventions. Her work involves diving deep into the nuances of human interaction to deduce insights that organizations can use to optimize their products and processes.

Molnár’s contribution is essential for ensuring that behavioral interventions are predictable and data-driven. Her expertise in Behavioural Science and Neuroscience allows BeHive to map out complex systems, such as a patient’s journey through a hospital, and identify the "frictions" that prevent optimal health outcomes.

19. Anna Nyvelt (BeHive Consulting)

Anna Nyvelt, a co-founder and Commercial Director at BeHive Consulting, focuses on the application and scaling of behavioral science know-how within organizations. She bridge the gap between scientific insights and the practical needs of clients in the healthcare, banking, and telecommunications sectors.

Nyvelt’s work helps organizations build their own internal capabilities in behavioral science, ensuring that innovative interventions are sustainable in the long term. Her leadership has helped BeHive achieve significant commercial success, with $544,000 in revenue in 2024, demonstrating the market demand for "human-centred design" in high-stakes industries.

20. Adewunmi Akingbola (Cambridge Public Health / Research ties to Hungary)

Adewunmi Akingbola is a researcher at Cambridge Public Health who has been recognized on the Forbes 30 Under 30 Europe list for his work in developing public health playbooks to improve data reliability. While his primary work is international, his research into Hepatitis C and health biases is highly relevant to the Hungarian scientific community, where data-driven public health is a growing priority.

Akingbola’s inclusion as a future leader reflects the increasing global integration of Hungarian science. His focus on addressing biases in health studies and improving the reliability of real-world data is crucial for the development of equitable healthcare solutions. His work serves as an inspiration for young Hungarian researchers who are increasingly looking beyond national borders to solve global health challenges.

Comparative Analysis of Funding and Maturity

The maturity of the Hungarian HealthTech ecosystem can be quantified by examining the funding status and strategic focus of its leading companies. There is a clear progression from early-stage, university-backed spin-offs to more mature firms capable of raising significant international capital.

Leader/Company	Primary Vertical	Maturity Stage	Key Funding/Support
Turbine AI	Oncology / In Silico	Series A	$30.7M (Accel, Mercia)
Genomate Health	Precision Oncology	Seed	$10.03M Total (Oktogon Ventures)
VRG Therapeutics	Cell & Gene Therapy	Series A	$5.47M (Szechenyi Funds)
XUND	Digital Diagnostics	Seed	€6M round (Lead Ventures)
NICOWL	Neonatal MedTech	Pre-Seed / Seed	EIT Health InnoStars Finalist
Cytocast	Whole-Cell Simulation	Pre-Seed	€1.9M round (University spin-off)
Poliloop	Biotech / Sustainability	Seed	$2.1M (Techstars)
MEROVA Health	Chronic Care (Diabetes)	Seed	HUF 100M (Hiventures)

This table illustrates the diverse range of funding sources, including traditional VC firms, state-owned funds like Hiventures, and international accelerators. The presence of both early-stage (Pre-Seed) and more established (Series A) companies suggests a healthy "pipeline" of innovation that will sustain the sector in the coming years.

Technological Trends: AI, Spheroids and the Electrome

The 20 leaders identified are at the forefront of several key technological trends that are reshaping the healthcare industry. These trends are not isolated but often interact to create more powerful solutions.

The Rise of In Silico and AI Diagnostics

The most dominant trend is the shift from physical to digital testing. Companies like Turbine AI and Cytocast are leading the way in "in silico" modeling, which uses AI to predict biological outcomes. This is mirrored in diagnostics, where firms like XUND and NICOWL use AI to analyse patient symptoms and behaviour, providing insights that were previously hidden in the data.

Scaling Personalised Medicine through Automation

A second critical trend is the automation of high-throughput analysis. Péter Horváth’s HCS-3DX system is the primary example of this, bringing industrial speed to the evaluation of 3D cell samples. This trend is essential for making personalised medicine accessible to the general population, as it reduces the manual labor and cost associated with tailoring treatments to individual patients.

Biophysical Manipulation and Targeted Delivery

Finally, there is a growing interest in the physical and chemical manipulation of cells. Terje Wimberger’s work with electromagnetic fields at Cellectric Biosciences and Professor Martinek’s caveolar entry sequences represent a movement toward highly targeted interventions. These technologies allow for the selective treatment of specific cells or the delivery of drugs directly to intracellular targets, minimising the systemic side effects that plague current therapies.

Conclusion: A Sustained Trajectory of Innovation

The Hungarian HealthTech and MedTech sectors have evolved into a sophisticated engine of innovation, driven by a new generation of leaders who possess a unique blend of scientific depth and entrepreneurial ambition. The transition from traditional pharmaceuticals to medical deep tech is supported by a robust infrastructure of state funding, university technology transfer, and international collaboration.

The 20 leaders identified in this report are not merely building companies; they are redefining the boundaries of what is possible in oncology, diagnostics, and patient care.

As the Hungarian ecosystem continues to mature, and as these leaders scale their innovations to a global audience, the impact on human health will be significant and enduring. The coordinated efforts of researchers, investors and policymakers have positioned Hungary as a vital hub for the life sciences in Europe, with a clear and ambitious vision for the future of healthcare.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech